Evaluation of three commercially available rapid assays for detection of IgG and/or IGM antibodies to SARS-CoV-2 (COVID-19) for assessment of contact persons’ immune status and termination of quarantine and self-isolation – a prospective pilot study
Not Applicable
- Conditions
- U07.1COVID-19, virus identified
- Registration Number
- DRKS00022083
- Lead Sponsor
- andesklinikum Neunkirchen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
All employees of the university hospital Krems with age >18 years, and with a history of direct contact to a COVID-19 patient without full personal protective equipment may be included.
Written consent to participate in the study is mandatory.
Exclusion Criteria
absence of consent; age <18 years; inadequate language skills for study information
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitivity and specificity of 3 commercially available SARS-CoV-2 antibody tests against the golden standard (ELISA)
- Secondary Outcome Measures
Name Time Method Evaluation of the immunologic Covid19 disease state of the participants